Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi: 10.3322/caac.21442..
DOI: 10.3322/caac.21442

Ledermann J.A., Raja F.A., Fotopoulou C., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24–vi32. doi: 10.1093/annonc/mdy157..
DOI: 10.1093/annonc/mdy157

Schorge J.O., Eisenhauer E.E., Chi D.S. Current surgical management of ovarian cancer. Hematol Oncol Clin North Am. 2012;26(1):93–109. doi: 10.1016/j.hoc.2011.10.004..
DOI: 10.1016/j.hoc.2011.10.004

The European Medicines Agency. European public assessment report. Avastin product information. Avastin-H-C-582-II-23, August 2008. Available at: http://www.emea.europa.eu/docs/en_GB/document_ library/EPAR_–_Assessment_Report_–_Variation/human/000582/WC500029270.pdf. Accessed January 24, 2009.http://www.emea.europa.eu/docs/en_GB/document_

The European Medicines Agency. European public assessment report. Avastin product information. Avastin-H-C-582-II-23, August 2008. Available at: http://www.emea.europa.eu/docs/en_GB/document_ library/EPAR_–_Assessment_Report_–_Variation/human/000582/WC500029270.pdf. Accessed January 24, 2009.http://www.emea.europa.eu/docs/en_GB/document_

Shih T., Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28(11):1779–1802. doi: 10.1016/j.clinthera.2006.11.015..
DOI: 10.1016/j.clinthera.2006.11.015

Perren T.J., Swart A.M., Pfisterer J., et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–2496. doi: 10.1056/NEJMoa1103799..
DOI: 10.1056/NEJMoa1103799

Oza A.M., Cook A.D., Pfisterer J., et al. ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936. doi: 10.1016/S1470-2045(15)00086-8..
DOI: 10.1016/S1470-2045(15)00086-8

Wade K.N.S., Brady M.F., Thai T., Wang Y., Zheng B., Salani R., Tewari K.S., Gray H.J., Bakkum-Gamez J.N., Burger R.A., Moore K.N., Bookman M.A. Measurements of adiposity as prognostic biomarkers for survival with antiangiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218. Clin Cancer Res. 2018;24(4):777-783. doi: 10.1158/1078-0432.CCR-17-1327..
DOI: 10.1158/1078-0432.CCR-17-1327

Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218. Clin Cancer Res. 2018;24(4):777-783. doi: 10.1158/1078-0432.CCR-17-1327..
DOI: 10.1158/1078-0432.CCR-17-1327

Stuart G., Avall-Lundqvist E., Du Bois A., et al. 3rd international ovarian cancer consensus Conference: outstanding issues for future consideration. Ann Oncol. 2005;16(suppl 8):viii36–viii38. doi: 10.1093/annonc/mdi965..
DOI: 10.1093/annonc/mdi965

Bergmann T.K., Gréen H., Brasch-Andersen C., et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol. 2011;67(7):693–700. doi: 10.1007/s00228-011-1007-6..
DOI: 10.1007/s00228-011-1007-6

Komatsu M., Wheeler H.E., Chung S., et al. Pharmacoethnicity in paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2015;21(19):4337–4346. doi: 10.1158/1078-0432.CCR-15-0133..
DOI: 10.1158/1078-0432.CCR-15-0133

Pignata S., Scambia G., Katsaros D., et al. Gynecologic Cancer InterGroup (GCIG) Investigators. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014;15(4):396–405. doi: 10.1016/S1470-2045(14)70049-X..
DOI: 10.1016/S1470-2045(14)70049-X

Academic.oup.com. ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis. Available at: https://academic.oup.com/annonc/article/28/suppl_5/ mdx440.039/4109951. Accessed January 18, 2019.https://academic.oup.com/annonc/article/28/suppl_5/

Academic.oup.com. ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis. Available at: https://academic.oup.com/annonc/article/28/suppl_5/ mdx440.039/4109951. Accessed January 18, 2019.https://academic.oup.com/annonc/article/28/suppl_5/

Marchetti C., De Felice F., Di Pinto A., et al. Dose-dense Weekly chemotherapy in advanced ovarian cancer: an updated metaanalysis of randomized controlled trials. Crit Rev Oncol Hematol. 2018;(125):30–34. doi: 10.1016/j.critrevonc.2018.02.016..
DOI: 10.1016/j.critrevonc.2018.02.016

Gonzalez-Martin A., Gladieff L., Tholander B. et al. OCTAVIA Investigators. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur J Cancer. 2013;49(18):3831–3838. doi: 10.1016/j.ejca.2013.08.002..
DOI: 10.1016/j.ejca.2013.08.002

Gonzalez-Martin A., Gladieff L., Tholander B., et al. OCTAVIA Investigators. Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer). Eur J Cancer. 2014;50(4):862–863. doi: 10.1016/j.ejca.2013.12.001..
DOI: 10.1016/j.ejca.2013.12.001

Chan J.K., Brady M.F., Penson R.T., et al. Weekly vs. Every-3-Week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016;374(8):738–748. doi: 10.1056/NEJMoa1505067..
DOI: 10.1056/NEJMoa1505067

Highlights of prescribing information. AVASTIN (bevacizumab) injection, for intravenous use Initial U.S. Approval: 2004. Available at: https://www.gene.com/download/pdf/avastin_prescribing.pdf.https://www.gene.com/download/pdf/avastin_prescribing.pdf

Highlights of prescribing information. AVASTIN (bevacizumab) injection, for intravenous use Initial U.S. Approval: 2004. Available at: https://www.gene.com/download/pdf/avastin_prescribing.pdf.https://www.gene.com/download/pdf/avastin_prescribing.pdf

FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery [webpage on the Internet]. June 2018. Available at: http://ovarian.org/about-ovarian-cancer/treatment/493-2018-06-13-21-09-18. Accessed January 18, 2019.http://ovarian.org/about-ovarian-cancer/treatment/493-2018-06-13-21-09-18

FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery [webpage on the Internet]. June 2018. Available at: http://ovarian.org/about-ovarian-cancer/treatment/493-2018-06-13-21-09-18. Accessed January 18, 2019.http://ovarian.org/about-ovarian-cancer/treatment/493-2018-06-13-21-09-18

Oza A.M., Selle F., Davidenko I., et al. Efficacy and safety of bevacizumab-containing therapy in newly diagnosed ovarian cancer: ROSiA single-arm phase 3B study. Int J Gynecol Cancer. 2017;27(1):50–58. doi: 10.1097/IGC.0000000000000836..
DOI: 10.1097/IGC.0000000000000836

A prospective randomised phase III trial to evaluate optimal treatment duration of firstline bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer. AGO-OVAR17. Ongoing, NCT number: NCT01462890, ClinicalTrials.gov.

Perren T.J., Swart A.M., Pfisterer J. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi:10.1056/NEJMoa1103799..
DOI: 10.1056/NEJMoa1103799

Kommoss S., Winterhoff B., Oberg A.L., et al. Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Clin Cancer Res. 2017;23(14):3794–3801. doi: 10.1158/1078-0432.CCR-16-2196..
DOI: 10.1158/1078-0432.CCR-16-2196

Marchetti C., Romito A., Musella A., et al. Combined plasma fibrinogen and neutrophil lymphocyte ratio in ovarian cancer prognosis may play a role? Int J Gynecol Cancer. 2018;28(5):939–944. doi: 10.1097/IGC.0000000000001233..
DOI: 10.1097/IGC.0000000000001233

Farolfi A., Petrone M., Scarpi E., et al. Inflammatory indexes as prognostic and predictive factors in ovarian cancer treated with chemotherapy alone or together with bevacizumab. A multicenter, retrospective analysis by the MITO group (MITO 24). Target Oncol. 2018;13(4):469–479. doi: 10.1007/s11523-018-0574-1..
DOI: 10.1007/s11523-018-0574-1

Stuart G.C., Kitchener H., Bacon M., et al. 2010 gynecologic cancer intergroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus Conference. Int J Gynecol Cancer. 2011;21(4):750–755. doi: 10.1097/IGC.0b013e31821b2568..
DOI: 10.1097/IGC.0b013e31821b2568

National Comprehensive Cancer Network. Epithelial ovarian cancer, including fallopian tube cancer and primary peritoneal cancer, 2015 ver1. 2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed January 18, 2019.http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf

National Comprehensive Cancer Network. Epithelial ovarian cancer, including fallopian tube cancer and primary peritoneal cancer, 2015 ver1. 2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed January 18, 2019.http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf

Vergote I., Tropé C.G., Amant F., et al. NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–953. doi: 10.1200/JCO.2011.36.9785..
DOI: 10.1200/JCO.2011.36.9785

Kehoe S., Hook J., Nankivell M., et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (chorus): an open-label, randomised, controlled, non-inferiority trial. The Lancet. 2015;386(9990):249–257. doi: 10.1016/S0140-6736(14)62223-6..
DOI: 10.1016/S0140-6736(14)62223-6

Rouzier R., Gouy S., Selle F., et al. Efficacy and safety of bevacizumabcontaining neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial. Eur J Cancer. 2017;(70):133–142. doi: 10.1016/j.ejca.2016.09.036..
DOI: 10.1016/j.ejca.2016.09.036

Daniele G., Lorusso D., Scambia G., et al. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): a subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. Gynecol Oncol. 2017;144(2):256–259. doi: 10.1016/j.ygyno.2016.12.011..
DOI: 10.1016/j.ygyno.2016.12.011

Salani R., O’Malley D.M., Copeland L.J., et al. Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer – a phase 1 study. Int J Gynecol Cancer. 2014;24(4):682–686. doi: 10.1097/IGC.0000000000000107..
DOI: 10.1097/IGC.0000000000000107

Petrillo M., Paris I., Vizzielli G., et al. Neoadjuvant chemotherapy followed by maintenance therapy with or without bevacizumab in unresectable high-grade serous ovarian cancer: a case-control study. Ann Surg Oncol. 2015;22(S3):S952–S958. doi: 10.1245/s10434-015-4651-8..
DOI: 10.1245/s10434-015-4651-8

RandomizedA Arandomized. Open-label, multicentric phase II trial of pembrolizumab (Keytruda®) with chemotherapy versus chemotherapy alone (standard of care) as neo adjuvant treatment of ovarian cancer not amenable to front line debulking surgery. NEOPEMBROV. Ongoing, NCT number: NCT03275506, ClinicalTrials.gov.

A phase III, multicenter, randomized, study of Atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with NewlyDiagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. IMagyn050. Ongoing, NCT number: NCT03038100, ClinicalTrials.gov.

A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors. Ongoing, NCT number: NCT00520013, ClinicalTrials.gov.

A randomized phase II trial of CarboplatinPaclitaxelBevacizumab vs CarboplatinPaclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination. MITO 25. Ongoing, NCT number: NCT03462212, ClinicalTrials.gov.